Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alto Neuroscience, Inc.ANRO · Entity 4755 | CHIEF MEDICAL OFFICER | February 11, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alto Neuroscience, Inc.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.71 · Expires 2036-02-10 | Direct | 124,000 |
Reported balance
After 2026-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-11 · Grant · Acquired 124,000 · Balance 124,000 F1: 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2026 Filed Feb 13, 2026 17:19 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 124,000 | $0.00 Strike: $16.71 | $0.00 |
DisclosureSEC source: 0002008707-26-000001 · wk-form4_1771021170.xml · derivative · entry 1 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,000 Underlying: Common Stock · 124,000 shares Expires 2036-02-10 F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 76,000 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 10 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,000 shares Expires 2035-02-04 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F7 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 76,000 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 9 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 76,000 shares Expires 2035-02-04 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F7 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 73,000 | Not disclosed Strike: $14.88 | Not disclosed |
DisclosureSEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 8 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,000 shares Expires 2034-02-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F6 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 73,000 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 7 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 73,000 shares Expires 2034-02-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F6 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 123,645 | Not disclosed Strike: $5.30 | Not disclosed |
DisclosureSEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 6 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 123,645 shares Expires 2033-12-19 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F5 · derivative.exercise_date: 25% of the shares underlying the option vested on December 20, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 123,645 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 5 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,645 Underlying: Common Stock · 123,645 shares Expires 2033-12-19 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F5 · derivative.exercise_date: 25% of the shares underlying the option vested on December 20, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 33,008 | Not disclosed Strike: $6.23 | Not disclosed |
DisclosureSEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 4 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,008 shares Expires 2033-04-13 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F4 · derivative.exercise_date: 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 33,008 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 3 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,008 Underlying: Common Stock · 33,008 shares Expires 2033-04-13 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F4 · derivative.exercise_date: 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 22,481 | Not disclosed Strike: $6.23 | Not disclosed |
DisclosureSEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 2 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,481 shares Expires 2032-08-01 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,481 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000064 · wk-form4_1752009714.xml · derivative · entry 1 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,481 Underlying: Common Stock · 22,481 shares Expires 2032-08-01 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 16:21 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 76,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001999480-25-000014 · wk-form4_1738963307.xml · derivative · entry 1 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 76,000 shares Expires 2035-02-04 F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 10, 2024 Filed Jul 11, 2024 16:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | PurchaseCommon Stock | 2,931 | $13.22 | $38,747.82 |
DisclosureSEC source: 0001415889-24-019488 · form4-07112024_040701.xml · nonDerivative · entry 3 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 39,851 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.04 to $13.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the "Friedman Trust"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 16:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | PurchaseCommon Stock | 1,388 | $13.15 | $18,252.20 |
DisclosureSEC source: 0001415889-24-019488 · form4-07112024_040701.xml · nonDerivative · entry 2 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 36,920 F2 · ownership.nature: The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the "Friedman Trust"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 16:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | PurchaseCommon Stock | 10,681 | $12.53 | $133,832.93 |
DisclosureSEC source: 0001415889-24-019488 · form4-07112024_040701.xml · nonDerivative · entry 1 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 35,532 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.05 to $13.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the "Friedman Trust"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 18:00 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 73,000 | $0.00 Strike: $14.88 | $0.00 |
DisclosureSEC source: 0001415889-24-006824 · form4-03052024_060306.xml · derivative · entry 1 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 73,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 16:38 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionSeries B Preferred Stock · Derivative | 16,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002936 · form4-02072024_090257.xml · derivative · entry 3 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 7,851 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. F2 · ownership.nature: The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the "Friedman Trust"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 16:38 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | PurchaseCommon Stock | 17,000 | $16.00 | $272,000.00 |
DisclosureSEC source: 0001415889-24-002936 · form4-02072024_090257.xml · nonDerivative · entry 2 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 24,851 F2 · ownership.nature: The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the "Friedman Trust"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 16:38 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionCommon Stock | 7,851 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-002936 · form4-02072024_090257.xml · nonDerivative · entry 1 Savitz Adam · CIK 0002008707 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 7,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. F2 · ownership.nature: The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the "Friedman Trust"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.